BMY News 50.51 04/21/2014 20:02:40 Bristol-Myers Squibb Company

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Bristol-Myers Squibb Company (BMY) 50.51 $BMY

Pfizer, Inc. Rebuffed: Is AstraZeneca plc Worth Another Try?
Stephen D., Simpson,, The Motley Fool - Motley Fool - 2 hrs 32 mins ago
Big-time pharma mergers have had a mixed track record, with large combinations often leading to significant cost reductions (and firings) in sales and administration but at the cost of large disruptions to R&D. Pfizer is apparently not afraid...

Final Glance: Pharmaceuticals companies
AP - 2 hrs 59 mins ago
NEW YORK (AP) — Shares of some top pharmaceuticals companies were up at the close of trading:

SmarTrend Watching for Potential Pullback in Shares of Bristol-Myers Squibb After 2.12% Gain
Comtex SmarTrend(R) - Mon Apr 21, 4:13PM CDT
Bristol-Myers Squibb (NYSE:BMY) traded in a range yesterday that spanned from a low of $49.58 to a high of $50.60. Yesterday, the shares gained 2.1%, which took the trading range above the 3-day high of $49.68 on volume of 5.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

Look for Shares of Bristol-Myers Squibb to Potentially Pullback after Yesterday's 2.12% Rise
Comtex SmarTrend(R) - Mon Apr 21, 4:13PM CDT
Bristol-Myers Squibb (NYSE:BMY) traded in a range yesterday that spanned from a low of $49.58 to a high of $50.60. Yesterday, the shares gained 2.1%, which took the trading range above the 3-day high of $49.68 on volume of 5.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

Galectin Therapeutics Rises on GR-MD-02 Update - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 21, 3:45PM CDT
Share price of Galectin Therapeutics jumped 12.9% after the company announced dosing of the first patient in cohort 2 of a phase I study on GR-MD-02.

Warfarin's Loss is Johnson & Johnson's Gain
Todd Campbell, The Motley Fool - Motley Fool - Mon Apr 21, 1:30PM CDT
Warfarin has long been doctor's go-to medicine for guarding against blood clots in post-operative or cardiovascular disease patients. However, an important shift that began in 2010 is having a profound effect on warfarin's dominance -- the approval...

Midday Glance: Pharmaceuticals companies
AP - Mon Apr 21, 12:20PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:

Bristol-Myers Squibb (BMY) Breaks Through Resistance at $49.78
Comtex SmarTrend(R) - Mon Apr 21, 11:44AM CDT
Bristol-Myers Squibb (NYSE:BMY) has opened bullishly above the pivot of $49.36 today and has reached the first level of resistance at $49.78. Should the shares continue to rise, the resistance pivots of $50.09 and $50.82 will be of interest.

Pfizer, AstraZeneca Rise On Report Of Merger Talks
at Investor's Business Daily - Mon Apr 21, 10:13AM CDT
Big pharmas Pfizer (PFE) and AstraZeneca (AZN) were both up in early trading on the stock market today after word got out Sunday that Pfizer had offered $101 billion to buy its rival. Citing unnamed sources, the U.K.'s Sunday Times said that the two...

Early Glance: Pharmaceuticals companies
AP - Mon Apr 21, 9:31AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are up at 10 a.m.:

Would Pfizer Buying AstraZeneca Actually Make Sense?
Sean Williams, The Motley Fool - Motley Fool - Mon Apr 21, 9:03AM CDT
Mondays are commonly referred to as "Merger Mondays" for a reason: the weekend gives companies time to hash out deals without the overbearing scrutiny of Wall Street analysts and investors who are also off for the weekend. Although no such deal was...

If This Biotech Drops Much Further I'm Going to Buy It!
Sean Williams, The Motley Fool - Motley Fool - Thu Apr 17, 12:05PM CDT
We've seen a little bit of a relief rally over the past couple of days in the overall market with the start of earnings season giving investors hope that the U.S. economy and corporations can keep motoring higher. On the all, though, it's been a...

Surveyed U.S. Physicians Expect Strong Uptake of Novel Oral Anticoagulants for the Treatment of VTE
PR Newswire - Thu Apr 17, 10:30AM CDT
Decision Resources Group finds that the novel oral anticoagulants (NOACs) will dramatically alter the treatment landscape for VTE treatment and secondary prophylaxis. Surveyed emergency room physicians and cardiologists indicate that they currently use Bayer/Janssen's Xarelto in 14 percent and 31 percent of their patients respectively, with over two-thirds of surveyed physicians increasing their use of Xarelto by 2015. Physicians indicate that Bristol-Myers Squibb/Pfizer's Eliquis is expected to garner a 19 percent patient share in 2015. Use of Boehringer Ingelheim's Pradaxa and Daiichi Sankyo's Savaysa are also expected to garner double-digit patient share in 2015, despite the requirement for preceding use of an injectable anticoagulant.

Will Merck & Co. Inc Unseat Biotech's Hottest Drug?
Dan Carroll, The Motley Fool - Motley Fool - Thu Apr 17, 8:30AM CDT
No drug has hit the market running like Gilead Sciences '  freshly approved oral hepatitis C drug Sovaldi. In a market that analysts estimate could be worth up to $20 billion, Sovaldi's made a huge impact in gaining regulatory approval first in the...

2 Reasons Why Merck & Co. Is Crushing the Dow
George Budwell, The Motley Fool - Motley Fool - Wed Apr 16, 5:30PM CDT
The Dow Jones Industrials  has finally lost some steam this year after its record-breaking gains in 2013. Specifically, the Dow Jones is presently down around 1% on the year. That said, some of its components are still marching northward at a...

Gilead Sciences, Inc. Feeling Sovaldi Pressure From All Sides
Cory Renauer, The Motley Fool - Motley Fool - Wed Apr 16, 5:30PM CDT
One of the sparks that ignited the recent biotech sell-off was the backlash over the cost of Gilead Sciences '  highly effective hepatitis C therapy. While much of the industry needed a reality check, it looks like the market has overreacted to...

Could This Small-Cap Biotech's Experimental Diabetes Drug Be a Game Changer?
Sean Williams, The Motley Fool - Motley Fool - Wed Apr 16, 1:05PM CDT
Nearly 26 million people in this country have diabetes, according to the Centers for Disease Control and Prevention. Statistics from research company PhRMA indicate  another 79 million are showing symptoms of pre-diabetes .  It's a disease with...
Scroll down for more posts ▼

Top 10 Most Recent News Articles

PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 534

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
Global Child Tests Purpose Travel's Expanding Media Reach

Updated Category News Views 45

Celebrity travel programming usually melts into the wallpaper, but Global Child is trying to make the scenery answer for itself. Its new season of Global Child “Travel & Purpose” puts Andrea Bocelli in Tuscany, Isabela Merced in Peru and John Malkovich in Croatia, while tying each destination to a broader local-good mission. That is a more thoughtful pitch than...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 731

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 126

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 332

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 270

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 303

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
UAE Ties Diplomacy, Media and AI Into a Shared Signal

Updated Category News Views 128

Influence is getting harder to measure, and easier to squander, which is why the message from Ajman deserves more than a polite nod. At the 2026 Ajman Media Forum, THE SIGNAL, Foreign Affairs Undersecretary Omar Obaid Alhesan Alshamsi made the UAE’s position plain: diplomacy and media are no longer separate lanes. Both operate on words, context, trust and the difficult...

Continue Reading
FASTEN Data Offers an Early Look at Ladera Closure

Updated Category News Views 137

Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...

Continue Reading
ModuleMD Takes Allergy EHR AI Beyond the Usual Hype Cycle

Updated Category News Views 398

Allergy Workflows Are Where This Has to Earn Its Keep Allergy clinics do not need another shiny dashboard clogging up a workstation. They need less typing, fewer handoffs, cleaner documentation, and fewer administrative chores slipping through the cracks while a packed day keeps moving. That is the practical lens for ModuleMD's ACAAI 2026 presentation in Phoenix: not...

Continue Reading

Top 5 Most Recently Viewed Articles

Christina Lake Cannabis Moves to Revise Debenture Terms

Updated Category News Views 176

Christina Lake Cannabis Plans to Amend Debenture Agreements VANCOUVER, British Columbia – Christina Lake Cannabis Corp. (the “Company” or “CLC” or “Christina Lake Cannabis”) (CSE: CLC) (OTCQB: CLCFF) (FRANKFURT: CLB) has announced a significant strategic initiative aimed at altering the terms of its convertible debentures, totaling an aggregate principal...

Continue Reading
Senseonics Secures $16 Million for CGM Expansion Efforts

Updated Category News Views 225

Significant Funding Announcement by Senseonics Senseonics Holdings (NYSE: SENS), a leader in medical technology focused on diabetes management, has announced an important agreement to boost its operations. Through a registered direct offering and a concurrent private placement, the company aims to raise approximately $16 million. This funding aligns with Senseonics'...

Continue Reading
XRP Mining: An Innovative Approach to Crypto Yield Generation

Updated Category News Views 144

Revolutionizing Cryptocurrency Mining with XRP As the cryptocurrency market continuously evolves at a rapid pace, traditional mining practices are being replaced by more intelligent and efficient methods. Among these, XRP Mining stands out as a groundbreaking approach that enables individuals to earn daily cryptocurrency income without needing costly hardware or intricate...

Continue Reading
Orgenesis Launches Trading on OTCQX Following Nasdaq Delisting

Updated Category News Views 94

Orgenesis Begins Trading on OTCQX Orgenesis Inc, a prominent player in the biotech sector dedicated to enhancing cell and gene therapies, has recently made a significant shift by commencing trading on the OTCQX Best Market under the ticker symbol "ORGS". This transition comes after the company faced delisting from the Nasdaq Stock Market due to not meeting the necessary...

Continue Reading
Investors Encouraged to Join Bath & Body Works Lawsuit

Updated Category News Views 178

Understanding the Bath & Body Works Class Action Lawsuit Bath & Body Works, Inc. (NYSE: BBWI) has come under scrutiny as a result of a class action lawsuit regarding securities fraud. This legal action comes on behalf of investors who purchased BBWI securities within a specific timeframe. If you fall under this category, you may have the opportunity to seek compensation...

Continue Reading